Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker NTRA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer NCT07214532 · Breast Neoplasms, Carcinoma, Ductal, Breast ctDNA-Guided Treatment Strategy | NTRA Natera, Inc. | Not applicable | Recruiting | 725 | May 15, 2032 | Registry ↗ |
| Oct 27, 2026 | A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of C… NCT07689812 · NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-sma… Signatera Genome ultra-sensitive ctDNA blood test | NTRA Natera, Inc. | Not applicable | Not yet recruiting | 920 | Aug 2034 | Registry ↗ |
| Aug 17, 2026 | Verification of Risk Assignment for Whole Chromosome Using SNP-based NIPT in Vanishing Twin Pregnan… NCT05004337 · Vanishing Twin, Trisomy 21 | NTRA Natera, Inc. | — | Completed | 136 | Nov 29, 2023 | Registry ↗ |
| Aug 13, 2026 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-muscle Invasive Bladder C… NCT07763197 · Non-Muscle Invasive Bladder Cancer, NMIBC | NTRA Natera, Inc. | — | Recruiting | 400 | Jul 2032 | Registry ↗ |
| Aug 6, 2026 | Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-N… NCT07750886 · Non-Hodgkin Lymphoma, T-Cell Lymphoma | NTRA Natera, Inc. | — | Recruiting | 200 | Apr 2032 | Registry ↗ |
| Jul 22, 2026 | Immunosuppression Optimization Using The Prospera Assay In Kidney Transplant Recipients (IMPAKT) NCT07718633 · Kidney Transplant, Immunosuppresion Prospera Immunosuppression Optimization | NTRA Natera, Inc. | Not applicable | Not yet recruiting | 750 | Dec 2027 | Registry ↗ |
| Jun 17, 2026 | Signatera Assessment in Early-Stage Endometrial Cancer NCT07339384 · Endometrial Cancer Signatera Genome ultra-sensitive ctDNA blood test | NTRA Natera, Inc. | Not applicable | Not yet recruiting | 1,010 | Oct 2034 | Registry ↗ |
| May 4, 2026 | Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esoph… NCT07565857 · Gastric-Esophageal Cancer Signatera Genome ultra-sensitive ctDNA blood test | NTRA Natera, Inc. | Not applicable | Not yet recruiting | 1,000 | Sep 2028 | Registry ↗ |
| May 4, 2026 | EXpanding Prenatal Cell Free DNA Screening Across moNogenic Disorders (EXPAND) NCT06808880 · Single Gene NIPT Single-gene Noninvasive Prenatal Testing (sgNIPT) | NTRA Natera, Inc. | — | Recruiting | 4,000 | Apr 2027 | Registry ↗ |
| Feb 27, 2026 | A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-… NCT06414603 · Heart Transplant Failure and Rejection The Prospera™ Test | NTRA Natera, Inc. | Not applicable | Active, not recruiting | 250 | Feb 2027 | Registry ↗ |
| Jan 15, 2026 | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 · Breast Cancer, Lung Cancer | NTRA Natera, Inc. | — | Recruiting | 9,600 | Jan 2035 | Registry ↗ |
| Dec 12, 2025 | Evaluation of the Natera Colorectal Cancer Screening Test in an Average Risk Population (FIND-CRC) NCT07046585 · Colo-rectal Cancer | NTRA Natera, Inc. | — | Recruiting | 25,000 | Jul 10, 2027 | Registry ↗ |
| May 22, 2025 | Prospera Test Evaluation in Cardiac Transplant (ProTECT) NCT05205551 · Heart Transplant Rejection | NTRA Natera, Inc. | — | Active, not recruiting | 411 | Oct 31, 2026 | Registry ↗ |
| May 22, 2025 | LAMBDA 002 (Lung Registry) Study NCT05170425 · Lung Transplant Rejection Prospera | NTRA Natera, Inc. | — | Active, not recruiting | 154 | Aug 2026 | Registry ↗ |
| Mar 18, 2025 | Study for the Prediction of Active Rejection in Organs Using Donor-derived Cell-free DNA Detection NCT03984747 · Transplant Rejection, Allograft Rejection | NTRA Natera, Inc. | — | Completed | 110 | Aug 23, 2024 | Registry ↗ |
| Jan 29, 2025 | Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Can… NCT06620627 · Colorectal Cancer Screening | NTRA Natera, Inc. | — | Recruiting | 5,000 | Jul 31, 2025 | Registry ↗ |
| Oct 29, 2024 | Development of Non-invasive Cell-free DNA to Supplant Invasive Biopsy in Heart Transplantation NCT05309382 · Heart Transplant Prospera | NTRA Natera, Inc. | — | Completed | 147 | Oct 2, 2024 | Registry ↗ |
| Sep 26, 2024 | Clinical Utility of the Addition of a SNP-based NIPT Zygosity Determination in Twin Pregnancy Manag… NCT05312814 · Twin to Twin Transfusion Syndrome, Pregnancy Complications | NTRA Natera, Inc. | — | Completed | 137 | May 15, 2023 | Registry ↗ |
| Aug 15, 2024 | BESPOKE Study of ctDNA Guided Immunotherapy NCT04761783 · Colorectal Cancer, Melanoma | NTRA Natera, Inc. | — | Completed | 290 | Dec 31, 2023 | Registry ↗ |
| Aug 6, 2024 | The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive) NCT04091984 · Kidney Transplant Rejection Prospera | NTRA Natera, Inc. | — | Active, not recruiting | 5,000 | Oct 1, 2026 | Registry ↗ |
| Apr 3, 2024 | Donor-Derived Cell-free DNA to DETect REjection in Cardiac Transplantation NCT05081739 · Heart Transplant Failure and Rejection Prospera Transplant Assessment, Endomyocardial biopsy | NTRA Natera, Inc. | Not applicable | Withdrawn | 0 | Jan 2025 | Registry ↗ |
| Dec 12, 2023 | BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer NCT04264702 · Colorectal Cancer, Colon Cancer | NTRA Natera, Inc. | — | Unknown | 1,788 | Sep 2025 | Registry ↗ |
| Sep 28, 2023 | Renasight Clinical Application, Review and Evaluation (RenaCARE) Study NCT05846113 · Kidney Diseases Renasight | NTRA Natera, Inc. | Not applicable | Unknown | 1,720 | Aug 2025 | Registry ↗ |
| Mar 23, 2023 | Prenatal Non-invasive Aneuploidy Test Utilizing SNPs Trial NCT01545674 · Trisomy 13, Trisomy 18 Blood Draw | NTRA Natera, Inc. | — | Terminated | 937 | Apr 2014 | Registry ↗ |
| Jan 29, 2021 | SNP-based Microdeletion and Aneuploidy RegisTry (SMART) NCT02381457 · 22q11 Deletion Syndrome, DiGeorge Syndrome | NTRA Natera, Inc. | — | Completed | 20,960 | Jun 2020 | Registry ↗ |
| Dec 30, 2020 | Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated… NCT01852708 · Trisomy 21, Trisomy 18 | NTRA Natera, Inc. | — | Completed | 1,059 | Oct 2020 | Registry ↗ |
| Feb 6, 2020 | Natera Ovarian Cancer Detection Assay NCT03485651 · Adnexal Mass | NTRA Natera, Inc. | — | Terminated | 12 | Nov 1, 2019 | Registry ↗ |
| Aug 26, 2019 | Multiple Gestation Study NCT02278536 · Trisomy 13, Trisomy 18 | NTRA Natera, Inc. | — | Completed | 354 | Mar 2019 | Registry ↗ |
| Aug 26, 2019 | Development of Non-invasive Prenatal Test for Microdeletion and Other Genetic Syndromes Based on Ce… NCT02109770 · Microdeletion Syndromes, Trisomy 21 | NTRA Natera, Inc. | — | Completed | 216 | Jun 2019 | Registry ↗ |
| Jun 13, 2019 | High Risk Multiple Gestation Study NCT02278874 · Trisomy 13, Trisomy 18 | NTRA Natera, Inc. | — | Completed | 99 | Dec 1, 2018 | Registry ↗ |
30 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 7:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances